HRP20151250T1 - Derivati izoksazolo-piridina - Google Patents
Derivati izoksazolo-piridina Download PDFInfo
- Publication number
- HRP20151250T1 HRP20151250T1 HRP20151250TT HRP20151250T HRP20151250T1 HR P20151250 T1 HRP20151250 T1 HR P20151250T1 HR P20151250T T HRP20151250T T HR P20151250TT HR P20151250 T HRP20151250 T HR P20151250T HR P20151250 T1 HRP20151250 T1 HR P20151250T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- methyl
- compound
- phenyl
- optionally substituted
- Prior art date
Links
- NABZXASCLFSKLF-UHFFFAOYSA-N [1,2]oxazolo[4,3-b]pyridine Chemical class C1=CC=NC2=CON=C21 NABZXASCLFSKLF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 14
- -1 benzyloxy, tetrahydropyridinyl Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 claims 2
- DBPRZHYSXRZSHX-UHFFFAOYSA-N 6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridine-3-carboxylic acid Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC1=CC=C(C(O)=O)C=N1 DBPRZHYSXRZSHX-UHFFFAOYSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Claims (14)
1. Spoj, naznačen time, da ima formulu I:
[image]
u kojoj
X je O ili NH;
R1 je fenil, piridinil ili pirimidinil, od kojih je svaki po želji supstituiran s 1,2 ili 3 halogena;
R2 je H ili CH3 ili CF3;
R3 i R6 su H, halogen, CN ili C1-7-alkil;
R4 je -C(O)-NRbRc, gdje Rb i Rc zajedno s dušikom na kojega su vezani, tvore heterociklilni dio skupine, po želji supstituiran s jednim ili više A;
R5 je H, CF3, benziloksi, tetrahidropiridinil opcijski supstituiran s jednim metilom, -C(O)-NRbRc, pri čemu je svaki od Rb i Rc neovisno H ili morfolinil;
A je hidroksi, okso, C1-7-alkil, C1-7-alkoksi, C1-7-haloaIkil, C1-7-hidroksialkil, halogen ili CN;
pri čemu se izraz „heterociklilni dio skupine" odnosi na monovalentni zasićeni ili djelomično zasićeni 3-člani do 7-člani monociklički sustav prstena, ili 9-člani do 10-člani biciklički sustav prstena, gdje se jedan, dva, tri ili četiri atoma ugljika toga prstena, zamjenjuje s N, O ili S, i s točkom priključenja na zasićenom ili djelomično nezasićenom prstenu od navedenog sustava prstena; ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema zahtjevu 1, naznačen time, da R2 je metil ili trifluorometil.
3. Spoj prema bilo kojem od zahtjeva 1 do 2, naznačen time, da R3 je H, CN ili metil.
4. Spoj prema bilo kojem od zahtjeva 1 do 3, naznačen time, da R6 je H, Br ili metil.
5. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time, da je heterociklilni dio skupine od R4 odabran od sljedećih: morfolinil, tiomorfolinil, 5,6,7,8-tetrahidro-[1,2,4]triazolo-[4,3-a]pirazinil, i 4,5,6,7-tetrahidro-pirazolo [1,5-a]pirimidinil, od kojih je svaki po želji supstituiran s jednim ili više A.
6. Spoj prema bilo kojem od zahtjeva 1 do 5, naznačen time, da R5 je H ili CF3.
7. Spoj prema bilo kojem od zahtjeva 1 do 6, naznačen time, da R5 je H ili CF3, R3 i R5 su H, halogen, CN ili C1-7-alkil.
8. Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time, da spoj je (1,1-diokso-1λ6-tiomorfolin-4-il)-{6-[3-(4-fluoro-fenil)-5-metil-izoksazol-4-ilmetoksi]-piridin-3-il}-metanon.
9. Spoj prema zahtjevu 8, naznačen time, da se on može dobiti pomoću reakcije spoja 6-[3-(4-fluoro-fenil)-5-metil-izoksazol-4-ilmetoksi]-nikotinska kiselina s tiomorfolin-S,S-dioksidom.
10. Spoj prema zahtjevu 9, naznačen time, da se spojevi 2-(1H-benzotriazol-1-il)-1,1,3,3-tetrametiluronij-tetrafluoroborat i tiomorfolin-S,S-dioksid, dodaju u otopinu od 6-[3-(4-fluoro-fenil)-5-metil-izoksazol-4-ilmetoksi]-nikotinske kiseline u DMF.
11. Spoj prema bilo kojem od zahtjeva 1 do 10, naznačen time, da se upotrebljava kao lijek.
12. Lijek, naznačen time, da sadrži barem jedan spoj formule I prema bilo kojem od zahtjeva 1 do 10.
13. Lijek prema zahtjevu 12, naznačen time, da se upotrebljava u liječenju kognitivnih poremećaja ili kao kognitivni pobuđivač.
14. Lijek prema zahtjevu 13, naznačen time, da se upotrebljava u liječenju Alzheimerove bolesti.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07122240 | 2007-12-04 | ||
EP14168581.8A EP2767536B1 (en) | 2007-12-04 | 2008-11-26 | Isoxazolo-pyridine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20151250T1 true HRP20151250T1 (hr) | 2015-12-18 |
Family
ID=40329314
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150348TT HRP20150348T1 (hr) | 2007-12-04 | 2015-03-27 | Derivati izoksazolo-piridina |
HRP20151250TT HRP20151250T1 (hr) | 2007-12-04 | 2015-11-20 | Derivati izoksazolo-piridina |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150348TT HRP20150348T1 (hr) | 2007-12-04 | 2015-03-27 | Derivati izoksazolo-piridina |
Country Status (34)
Country | Link |
---|---|
US (6) | US20090143371A1 (hr) |
EP (2) | EP2227467B1 (hr) |
JP (1) | JP5301557B2 (hr) |
KR (2) | KR20120102117A (hr) |
CN (1) | CN101889010B (hr) |
AR (1) | AR069523A1 (hr) |
AU (1) | AU2008333326B2 (hr) |
BR (1) | BRPI0820112B8 (hr) |
CA (1) | CA2707648C (hr) |
CL (1) | CL2008003591A1 (hr) |
CO (1) | CO6351788A2 (hr) |
CR (1) | CR11454A (hr) |
CY (2) | CY1116119T1 (hr) |
DK (2) | DK2227467T3 (hr) |
EC (1) | ECSP10010230A (hr) |
ES (2) | ES2550994T3 (hr) |
HK (1) | HK1149756A1 (hr) |
HR (2) | HRP20150348T1 (hr) |
HU (1) | HUE025545T2 (hr) |
IL (1) | IL205759A (hr) |
MA (1) | MA31865B1 (hr) |
MX (1) | MX2010005717A (hr) |
MY (1) | MY156747A (hr) |
NZ (1) | NZ585308A (hr) |
PE (2) | PE20130242A1 (hr) |
PL (2) | PL2227467T3 (hr) |
PT (2) | PT2767536E (hr) |
RS (2) | RS53877B1 (hr) |
RU (1) | RU2484091C2 (hr) |
SI (2) | SI2767536T1 (hr) |
TW (1) | TWI363624B (hr) |
UA (1) | UA100132C2 (hr) |
WO (1) | WO2009071476A1 (hr) |
ZA (1) | ZA201003631B (hr) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2227467T3 (pl) | 2007-12-04 | 2015-05-29 | Hoffmann La Roche | Pochodne izoksazolo-pirydyny |
US20100216827A1 (en) * | 2008-10-21 | 2010-08-26 | Metabolex, Inc. | Aryl gpr120 receptor agonists and uses thereof |
US8748623B2 (en) | 2009-02-17 | 2014-06-10 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as CXCR2 modulators |
US8389550B2 (en) * | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
US8222246B2 (en) * | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
US20100280019A1 (en) * | 2009-04-30 | 2010-11-04 | Roland Jakob-Roetne | Isoxazoles |
WO2010127976A1 (en) * | 2009-05-05 | 2010-11-11 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives |
AU2010244552A1 (en) * | 2009-05-05 | 2011-09-29 | F. Hoffmann-La Roche Ag | Isoxazole-pyrazole derivatives |
CA2759598C (en) * | 2009-05-05 | 2017-09-12 | F. Hoffmann-La Roche Ag | Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders |
SG175318A1 (en) | 2009-05-07 | 2011-11-28 | Hoffmann La Roche | Isoxazole-pyridine derivatives as gaba modulators |
RU2012116124A (ru) * | 2009-09-21 | 2013-10-27 | Вандербилт Юниверсити | О-БЕНЗИЛ НИКОТИНАМИДНЫЕ АНАЛОГИ КАК ПОЗИТИВНЫЕ АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ mGluR5 |
AU2011210765A1 (en) | 2010-01-28 | 2012-09-13 | President And Fellows Of Harvard College | Compositions and methods for enhancing proteasome activity |
US20130252972A1 (en) | 2010-07-19 | 2013-09-26 | Syngenta Crop Protection Llc | Isoxazole, isothiazole, furane and thiophene compounds as microbicides |
US20130210836A1 (en) | 2010-07-19 | 2013-08-15 | Syngenta Crop Protection Llc | Microbicides |
US8779149B2 (en) | 2010-08-23 | 2014-07-15 | Syntrix Biosystems, Inc. | Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators |
EP2457569A1 (en) | 2010-11-05 | 2012-05-30 | F. Hoffmann-La Roche AG | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
WO2012059482A1 (en) * | 2010-11-05 | 2012-05-10 | F. Hoffmann-La Roche Ag | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
CN103635230B (zh) | 2011-05-12 | 2017-10-31 | 普罗蒂斯特斯治疗公司 | 蛋白内稳态调节剂 |
US8604062B2 (en) * | 2011-10-20 | 2013-12-10 | Hoffman-La Roche Inc. | Process for the preparation of isoxazolyl-methoxy nicotinic acids |
US8785435B2 (en) * | 2011-10-20 | 2014-07-22 | Hoffmann-La Roche Inc. | Solid forms |
ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
PT3738434T (pt) | 2011-12-28 | 2023-11-13 | Global Blood Therapeutics Inc | Intermediários para obter compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos |
US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
EP2877463B1 (en) * | 2012-06-26 | 2018-11-07 | Saniona A/S | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
US9475797B2 (en) | 2012-06-26 | 2016-10-25 | Saniona A/S | Phenyl triazole derivative and its use for modulating the GABAA receptor complex |
WO2014001280A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
WO2014001279A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
WO2014001278A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
WO2014116228A1 (en) | 2013-01-25 | 2014-07-31 | President And Fellows Of Harvard College | Usp14 inhibitors for treating or preventing viral infections |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EA033555B1 (ru) * | 2013-03-15 | 2019-10-31 | Global Blood Therapeutics Inc | Фармацевтические композиции для лечения серповидно-клеточного нарушения |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
PE20160078A1 (es) | 2013-03-15 | 2016-03-02 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina |
EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
MY189995A (en) | 2014-02-07 | 2022-03-22 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
JP2017071553A (ja) * | 2014-02-25 | 2017-04-13 | 味の素株式会社 | ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物 |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
CN106810542B (zh) * | 2015-11-30 | 2021-03-09 | 苏州开拓药业股份有限公司 | 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法 |
US11020382B2 (en) | 2015-12-04 | 2021-06-01 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
AR108435A1 (es) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
HRP20220468T1 (hr) * | 2016-12-08 | 2022-05-27 | F. Hoffmann - La Roche Ag | Novi derivati izoksazolil etera kao gaba a alpha5 pam |
CA3074110A1 (en) * | 2017-08-28 | 2019-03-07 | University Of Maryland, Baltimore | Novel gamma aminobutyric acid type a receptor modulators for mood disorders |
CA3086792A1 (en) * | 2017-12-22 | 2019-06-27 | Bayer Aktiengesellschaft | Hydroxyisoxazolines and derivatives thereof |
MX2020013518A (es) * | 2018-06-13 | 2021-02-26 | Hoffmann La Roche | Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) del receptor de acido gamma-aminobutirico a alfa5 (gaba a alfa5). |
BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
HU231223B1 (hu) | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
ES2966707T3 (es) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
EP4126858A1 (en) | 2020-03-26 | 2023-02-08 | Richter Gedeon Nyrt. | Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators |
EP4334301A1 (en) | 2021-05-05 | 2024-03-13 | University College Cardiff Consultants Limited | Heteroaryl compounds useful in the treatment of cognitive disorders |
CN116854680A (zh) * | 2022-03-28 | 2023-10-10 | 上海赛默罗生物科技有限公司 | 异噁唑-杂环类衍生物、药物组合物和用途 |
CN115286636A (zh) * | 2022-10-08 | 2022-11-04 | 上海赛默罗生物科技有限公司 | 烟酰胺晶型及其制备方法和用途 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3812225A1 (de) * | 1988-04-13 | 1989-10-26 | Basf Ag | Isoxazol(isothiazol)-5-carbonsaeureamide |
ES2255294T3 (es) | 1998-08-07 | 2006-06-16 | Chiron Corporation | Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos. |
DE19920791A1 (de) * | 1999-05-06 | 2000-11-09 | Bayer Ag | Substituierte Benzoylisoxazole |
GB0125086D0 (en) | 2001-10-18 | 2001-12-12 | Merck Sharp & Dohme | Novel compounds |
WO2003099793A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
GB0221443D0 (en) * | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
BRPI0511099A (pt) * | 2004-05-14 | 2007-12-26 | Irm Llc | compostos e composições como moduladores de ppar |
BRPI0516842A (pt) * | 2004-10-01 | 2008-09-23 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por lxr alfa e/ou lxr beta agonistas e uso desses compostos |
EP1899299B1 (en) * | 2005-06-27 | 2010-10-20 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
CA2623043A1 (en) * | 2005-09-19 | 2007-04-12 | F. Hoffman-La Roche Ag | Isoxazolo derivatives as gaba a alpha5 inverse agonists |
BRPI0617306A2 (pt) * | 2005-10-11 | 2011-07-19 | Hoffmann La Roche | derivados de isoxazol |
CA2633425A1 (en) * | 2005-12-23 | 2007-06-28 | F. Hoffmann-La Roche Ag | Aryl-isoxazolo-4-yl-oxadiazole derivatives |
JP2009521516A (ja) | 2005-12-27 | 2009-06-04 | エフ.ホフマン−ラ ロシュ アーゲー | アリール−イソオキサゾール−4−イル−イミダゾール誘導体 |
CA2633536A1 (en) | 2005-12-27 | 2007-07-05 | F. Hoffmann-La Roche Ag | Aryl-isoxazol-4-yl-imidazo[1, 5-a]pyridine derivatives |
RU2426732C2 (ru) | 2006-01-17 | 2011-08-20 | Ф. Хоффманн-Ля Рош Аг | АРИЛ-ИЗОКСАЗОЛ-4-ИЛ-ИМИДАЗО[1,2-a]ПИРИДИН, ПРИГОДНЫЙ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА ЧЕРЕЗ ПОСРЕДСТВО GABA-РЕЦЕПТОРОВ |
US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
PL2227467T3 (pl) | 2007-12-04 | 2015-05-29 | Hoffmann La Roche | Pochodne izoksazolo-pirydyny |
CA2706990C (en) | 2007-12-04 | 2016-05-10 | F. Hoffmann-La Roche Ag | Isoxazolo-pyrazine derivatives |
US20100280019A1 (en) * | 2009-04-30 | 2010-11-04 | Roland Jakob-Roetne | Isoxazoles |
-
2008
- 2008-11-26 PL PL08857137T patent/PL2227467T3/pl unknown
- 2008-11-26 RS RS20150176A patent/RS53877B1/en unknown
- 2008-11-26 PL PL14168581T patent/PL2767536T3/pl unknown
- 2008-11-26 SI SI200831532T patent/SI2767536T1/sl unknown
- 2008-11-26 ES ES14168581.8T patent/ES2550994T3/es active Active
- 2008-11-26 PT PT141685818T patent/PT2767536E/pt unknown
- 2008-11-26 AU AU2008333326A patent/AU2008333326B2/en active Active
- 2008-11-26 CA CA2707648A patent/CA2707648C/en active Active
- 2008-11-26 UA UAA201008007A patent/UA100132C2/ru unknown
- 2008-11-26 SI SI200831370T patent/SI2227467T1/sl unknown
- 2008-11-26 EP EP08857137.7A patent/EP2227467B1/en active Active
- 2008-11-26 BR BRPI0820112A patent/BRPI0820112B8/pt active IP Right Grant
- 2008-11-26 KR KR1020127018310A patent/KR20120102117A/ko not_active Application Discontinuation
- 2008-11-26 MY MYPI2010002566A patent/MY156747A/en unknown
- 2008-11-26 DK DK08857137.7T patent/DK2227467T3/en active
- 2008-11-26 RS RS20150703A patent/RS54355B1/en unknown
- 2008-11-26 WO PCT/EP2008/066225 patent/WO2009071476A1/en active Application Filing
- 2008-11-26 CN CN2008801193998A patent/CN101889010B/zh active Active
- 2008-11-26 PT PT08857137T patent/PT2227467E/pt unknown
- 2008-11-26 ES ES08857137T patent/ES2531023T3/es active Active
- 2008-11-26 RU RU2010123923/04A patent/RU2484091C2/ru active
- 2008-11-26 EP EP14168581.8A patent/EP2767536B1/en active Active
- 2008-11-26 NZ NZ585308A patent/NZ585308A/en unknown
- 2008-11-26 DK DK14168581.8T patent/DK2767536T3/en active
- 2008-11-26 HU HUE14168581A patent/HUE025545T2/en unknown
- 2008-11-26 KR KR1020107012058A patent/KR101237576B1/ko active IP Right Grant
- 2008-11-26 JP JP2010536409A patent/JP5301557B2/ja active Active
- 2008-11-26 MX MX2010005717A patent/MX2010005717A/es active IP Right Grant
- 2008-12-01 PE PE2012002214A patent/PE20130242A1/es not_active Application Discontinuation
- 2008-12-01 US US12/325,293 patent/US20090143371A1/en not_active Abandoned
- 2008-12-01 PE PE2008002002A patent/PE20091073A1/es active IP Right Grant
- 2008-12-01 TW TW097146632A patent/TWI363624B/zh active
- 2008-12-02 AR ARP080105242A patent/AR069523A1/es active IP Right Grant
- 2008-12-02 CL CL2008003591A patent/CL2008003591A1/es unknown
-
2010
- 2010-05-13 IL IL205759A patent/IL205759A/en active IP Right Grant
- 2010-05-14 CO CO10058230A patent/CO6351788A2/es active IP Right Grant
- 2010-05-21 CR CR11454A patent/CR11454A/es unknown
- 2010-05-21 ZA ZA2010/03631A patent/ZA201003631B/en unknown
- 2010-05-27 MA MA32871A patent/MA31865B1/fr unknown
- 2010-06-03 EC EC2010010230A patent/ECSP10010230A/es unknown
-
2011
- 2011-04-19 HK HK11103951.8A patent/HK1149756A1/xx unknown
-
2012
- 2012-02-10 US US13/370,444 patent/US8518974B2/en active Active
-
2013
- 2013-06-12 US US13/916,191 patent/US8877782B2/en active Active
- 2013-06-12 US US13/916,264 patent/US8877783B2/en active Active
- 2013-06-12 US US13/916,317 patent/US9073908B2/en active Active
- 2013-06-12 US US13/916,068 patent/US8846719B2/en active Active
-
2015
- 2015-03-16 CY CY20151100262T patent/CY1116119T1/el unknown
- 2015-03-27 HR HRP20150348TT patent/HRP20150348T1/hr unknown
- 2015-11-09 CY CY20151100999T patent/CY1116902T1/el unknown
- 2015-11-20 HR HRP20151250TT patent/HRP20151250T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20151250T1 (hr) | Derivati izoksazolo-piridina | |
JP6236173B2 (ja) | 脊髄性筋萎縮症を処置するための化合物 | |
ES2377849T3 (es) | Compuestos amino-heterocíclicos | |
ES2428401T3 (es) | Derivados de 7-aril-1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 | |
JP2013515729A5 (hr) | ||
HRP20160647T1 (hr) | Novi heterociklički derivati i njihova uporaba u liječenju neuroloških poremećaja | |
HRP20150868T1 (hr) | Derivati kinolina i kinoksalina kao inhibitori kinaze | |
JP2009529047A5 (hr) | ||
JP2008513498A5 (hr) | ||
CN101534824A (zh) | 作为化学活素受体拮抗剂的氨基吡咯烷 | |
ECSP056115A (es) | ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA | |
JP2014513139A5 (hr) | ||
ATE424402T1 (de) | Imidazopyridinverbindungen | |
TW201028422A (en) | Amino-heterocyclic compounds | |
CN107417684A (zh) | 杂环丙烯酰胺 | |
HRP20170484T1 (hr) | Novi kondenzirani spojevi piridina kao inhibitori kazeinske kinaze | |
JP2016523270A5 (hr) | ||
JP2016523911A5 (hr) | ||
HRP20140451T1 (hr) | Derivati izoksazola i njihova uporaba kao pojaäśivaäśa metabotropnih glutamatnih receptora | |
JP2010523522A5 (hr) | ||
ECSP077424A (es) | Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3 | |
JP2009504764A5 (hr) | ||
HRP20140312T1 (hr) | Derivati 1-heterociklil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona i njihova uporaba kao modulatori za pde9a | |
JP2016506962A5 (hr) | ||
CN106211770B (zh) | 作为γ‑分泌酶调节剂的色烯和1,1A,2,7B‑四氢环丙烷并[c]色烯吡啶并吡嗪二酮 |